Arcalyst 200 MG
Ended Awarded Last action
- Contract number
- 36C24526N0418
- Awardee
-
Kiniksa Pharmaceuticals (Uk), LTD. UEI HBHWNLNMHSV5
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $34,023
Award facts
- Contract value 100% obligated
- $34,022.62 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- London W1S, UK
Award details come from SAM.gov/FPDS.
About this award
The Department of Veterans Affairs, through Veterans Integrated Service Network 5, awarded a $34,022.62 firm fixed-price delivery order to Kinikska Pharmaceuticals (UK), LTD. for the supply of Arcalyst 200 mg on March 18, 2026. The contract, with an ultimate completion date of March 24, 2026, represents a pharmaceutical supply delivery under the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). No set-aside designation was used in this procurement, indicating open competition. Kinikska Pharmaceuticals serves as the prime contractor with no identified subcontractors, and performance will occur at the company's facility in London, United Kingdom.
This delivery order operates within the framework of Kinikska's existing indefinite delivery vehicles with the VA, including a $5.9 million Blanket Purchase Agreement with the VA National Acquisition Center effective through November 2026. Arcalyst (Rilonacept) is a specialized injectable medication indicated for treating chronic inflammatory disorders including recurrent pericarditis and cryopyrin-associated periodic syndromes. Kinikska has maintained a consistent role as a federal pharmaceutical supplier to the VA and Department of Justice, with documented delivery order obligations exceeding $1.7 million since October 2021, making this award part of the company's ongoing pharmaceutical supply relationship supporting VA healthcare operations across multiple service networks.
Quick answers
Who was awarded contract 36C24526N0418?
36C24526N0418 was awarded to Kiniksa Pharmaceuticals (Uk), LTD. by Veterans Integrated Service Network 5 (Veterans Health Administration) on March 18, 2026.
How much is contract 36C24526N0418 worth?
The government has obligated $34,023 on 36C24526N0418.
Is contract 36C24526N0418 an order under another contract?
Yes. 36C24526N0418 is a delivery order under 36F79722D0002, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0418 competed?
The extent of competition for 36C24526N0418 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award